{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Lymphoma&page=2", "query": { "condition": "Metastatic Lymphoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Lymphoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T12:28:24.868Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00301951", "title": "Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 7, "start_date": "2004-09", "completion_date": "2009-07", "has_results": false, "last_update_posted_date": "2017-10-12", "last_synced_at": "2026-07-24T12:28:24.868Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00301951" }, { "nct_id": "NCT00889408", "title": "DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "DT2219ARL", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 25, "start_date": "2013-12-02", "completion_date": "2014-07-21", "has_results": false, "last_update_posted_date": "2017-12-02", "last_synced_at": "2026-07-24T12:28:24.868Z", "location_count": 3, "location_summary": "Minneapolis, Minnesota • Houston, Texas • Temple, Texas", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Houston", "state": "Texas" }, { "city": "Temple", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00889408" }, { "nct_id": "NCT07082868", "title": "A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Primary Central Nervous System Lymphoma (PCNSL)", "Primary Central Nervous System Lymphoma", "Relapsed Primary Central Nervous System Lymphoma", "Refractory Primary Central Nervous System Lymphoma", "Central Nervous System Lymphoma", "Secondary Central Nervous System Lymphoma", "Secondary Central Nervous System Lymphoma (SCNSL)" ], "interventions": [ { "name": "ibrutinib", "type": "DRUG" }, { "name": "Epcoritamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2025-08-13", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-07-24T12:28:24.868Z", "location_count": 8, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07082868" }, { "nct_id": "NCT01644968", "title": "Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "Cohort 1 anti-OX40", "type": "DRUG" }, { "name": "Cohort 2 anti-OX40", "type": "DRUG" }, { "name": "Cohort 3 anti-OX40", "type": "DRUG" }, { "name": "Tetanus Day 29", "type": "BIOLOGICAL" }, { "name": "Tetanus Day 1", "type": "BIOLOGICAL" }, { "name": "KLH Day 1", "type": "BIOLOGICAL" }, { "name": "KLH Day 29", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2003-11", "completion_date": "2017-04", "has_results": false, "last_update_posted_date": "2022-05-17", "last_synced_at": "2026-07-24T12:28:24.868Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01644968" }, { "nct_id": "NCT04084067", "title": "Indocyanine Green (ICG) Guided Tumor Resection", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplastic Disease", "Solid Tumor" ], "interventions": [ { "name": "Indocyanine Green", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 230, "start_date": "2020-02-07", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-07-24T12:28:24.868Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04084067" }, { "nct_id": "NCT05351593", "title": "Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "CNS Lymphoma", "Primary Central Nervous System Lymphoma", "Secondary Central Nervous System Lymphoma" ], "interventions": [ { "name": "Tafasitamab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "James Rubenstein", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2022-06-08", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-07-24T12:28:24.868Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05351593" }, { "nct_id": "NCT00045292", "title": "Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "acyclovir", "type": "DRUG" }, { "name": "acyclovir sodium", "type": "DRUG" }, { "name": "valacyclovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": null, "start_date": "2002-04", "completion_date": "2004-10", "has_results": false, "last_update_posted_date": "2010-09-21", "last_synced_at": "2026-07-24T12:28:24.868Z", "location_count": 6, "location_summary": "Duarte, California • Stanford, California • Omaha, Nebraska + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Dallas", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00045292" }, { "nct_id": "NCT04870944", "title": "CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Midline Glioma, H3 K27-Altered", "Metastatic Malignant Neoplasm in the Central Nervous System", "Recurrent Diffuse Intrinsic Pontine Glioma", "Recurrent Diffuse Midline Glioma, H3 K27-Altered", "Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Primary Malignant Central Nervous System Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Primary Malignant Central Nervous System Neoplasm" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspirate", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "FACT Complex-targeting Curaxin CBL0137", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 63, "start_date": "2022-01-28", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-07-24T12:28:24.868Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04870944" }, { "nct_id": "NCT03311412", "title": "Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Cancer", "Solid Tumor", "Lymphoma" ], "interventions": [ { "name": "Sym021", "type": "DRUG" }, { "name": "Sym022", "type": "DRUG" }, { "name": "Sym023", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Symphogen A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2017-11-20", "completion_date": "2022-03-23", "has_results": false, "last_update_posted_date": "2023-05-30", "last_synced_at": "2026-07-24T12:28:24.868Z", "location_count": 3, "location_summary": "Grand Rapids, Michigan • Houston, Texas • San Antonio, Texas", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03311412" }, { "nct_id": "NCT00003395", "title": "Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "arsenic trioxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "17 Years", "maximum_age": null, "sex": "ALL", "summary": "17 Years and older" }, "enrollment_count": null, "start_date": "1998-04", "completion_date": "2000-03", "has_results": false, "last_update_posted_date": "2013-06-25", "last_synced_at": "2026-07-24T12:28:24.868Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003395" } ] }